Patent · US Active

Crystalline forms of ponatinib hydrochloride

US9725454B2 · kind B2 · utility

2Cited by

0References

13Claims

0Family size

Assignee

Sandoz AG · CH

Inventors

Marijan Stefinovic · Kundl, AT
Hayley Reece · Scotland, GB
Asha Sunkara · Scotland, GB

Key dates

Filing date	Jul 4, 2014
Grant date	Aug 8, 2017
Priority date	—
Expiry date	Jul 4, 2034

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure relates to polymorphic forms of the hydrochloride salt of ponatinib (“compound 1”) and to processes for the preparation of these polymorphic forms. The present disclosure also generally relates to a pharmaceutical composition comprising the forms, as well of methods of using the form(s) in the treatment of disorders associated with pathological cellular proliferation, such as neoplasms, and cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.